All NSAIDs, including NALFON®, have the same cardiovascular warning: They may increase the chance of heart attack or stroke that can lead to death.  This chance increases with longer use of NSAID medicines and in people who have heart disease.  


The Only Marketed Non-Steroidal Anti-Inflammatory Drug (NSAID)
with Over 40 Years of Clinician Use and in Excess of 37 Million Prescriptions



NALFON® Capsules are indicated for relief of mild to moderate pain in adults, relief of the signs and symptoms of rheumatoid arthritis and the relief of the signs and symptoms of osteoarthritis.  

Carefully consider the potential benefits and risks of NALFON® and other treatment options before deciding to use NALFON®.  Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.  

Important Safety Information

Cardiovascular Risk
  • Non-Steroidal Anti-inflammatory Drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, myocardial infraction, and stroke, which can be fatal.  This risk may increase with duration of use.  Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS section of full Prescribing Information).
  • Nalfon is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (See WARNINGS section of full Prescribing Information).
Gastrointestinal Risk
  • NSAIDs cause an increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines, which can be fatal.  These events can occur at any time during use and without warning symptoms.  Elderly patients are at greater risk for serious gastrointestinal events (See WARNINGS section of full Prescribing Information).  

Nalfon is contraindicated in patients who have shown hypersensitivity to fenoprofen calcium.  Nalfon should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.  Severe, rarely fatal, anaphyiactic like reactions to NSAIDs have been reported in such patients.  Nalfon is contraindicated in patients with a history of significantly impaired renal function.  

Prescribing Benefits

  • 99% Bound to Plasma Proteins
  • Less than a 2% discontinuation rate due to GI adverse events
  • 15-30 minute onset of action
  • Patient compliant T.I.D (8hr) dosing

For further information on Nalfon, please see full Prescribing Information.
Copyright 2012-2013 Xspire Pharma.  All rights reserved.
Website Builder